Stimulation of Mammary Tumorigenesis and Suppression of Uterine Adenomyosis by Temporary Inhibition of Pituitary Prolactin Secretion during Youth in Mice

article OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-06

Temporary inhibition of prolactin secretion in young mice enhanced mammary tumorigenesis but suppressed uterine adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effects of daily subcutaneous injections of 0.2 mg CB-154 (bromocriptine-mesilate), a potent suppressor of pituitary prolactin secretion, between 4 and 11 weeks of age on the occurrence of spontaneous mammary tumors and adenomyosis, a hyperplasia of endometrial tissue, were studied in the SHN strain of virgin mice. While there was little difference in mammary tumor incidence between experimental and control mice until 9 months of age, mammary tumor incidence in the experimental mice given CB-154 was significantly enhanced and surpassed that in the control after 10 months; 25 (53.2%), 31 (66.0%), and 36 (75.5%) of 47 experimental mice and 20 (27.5%), 23 (33.3%), and 34 (49.3%) of 69 control mice developed mammary tumors at 10, 11, and 12 months of age, respectively. In contrast, no adenomyosis appeared in 39 experimental mice at necropsy at 12 months of age, while 15 (46.9%) of 32 control mice developed it. Furthermore, five mice (15.6%) of the control had numerous subserosal nodules, an advanced state of adenomyosis. No significant correlation was observed in the control mice between the occurrence of mammary tumors and that of adenomyosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715adenomyosis

MeSH descriptors

Endometriosis Mammary Neoplasms, Experimental Prolactin Age Factors Animals Bromocriptine Bromocriptine Endometriosis Female Mammary Neoplasms, Experimental Mice Mice, Inbred Strains Prolactin

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (12)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:00.881616+00:00
License: CC0 · commercial use OK